Abstract:
PURPOSE: The rheumatoid arthritis diagnosis kit is provided to diagnose rheumatoid arthritis more quickly and correctly by detecting the citrullinemic autoantigen within the specimen sample. CONSTITUTION: An antigen detection method for rheumatoid arthritis diagnosis comprises step of detecting the citrullinemic autoantigen from the biological specimen. The detection of the citrullinemic autoantigen detects the citrullinemic autoantigen from the biological specimen by treating the primary antibody that includes variable domain of light chain having sequence number 4 of amino acid and variable domain of heavy chain having sequence number 3 of amino acid in the biological specimen and treating its antigen-binding fragment. The rheumatoid arthritis diagnostic kit includes the monoclonal antibody or its antigen-binding fragment that specifically unites with the citrullinemic protein.
Abstract:
PURPOSE: A fusion protein is provided to suppress T cell activity and to prevent or treat arthritis. CONSTITUTION: A fusion protein contains CTLA4(cytotoxic T-lymphocyte antigen 4) and IL21R(Interleukin-21 receptor). The fusion protein has an amino acid of sequence number 1. IL21R and CTLA4 have amino acid sequences of sequence numbers 2 and 3, respectively. The fusion protein additionally contains an immunoglobulin Fc region at N-terminal or C-terminal. A transformant is prepared by transforming a host cell with a recombinant vector containing a gene encoding the fusion protein. [Reference numerals] (AA) Stimulation (-); (BB) Stimulation (+); (CC) CTLA4 +IL-21Fc dual target(fusion protein)
Abstract:
PURPOSE: A pharmaceutical composition containing meclizine is provided to protect cartilage and bone tissue and to prevent and treat arthritis. CONSTITUTION: A pharmaceutical composition for preventing and treating arthritis contains a compound of chemical formula 1 or a pharmaceutically acceptable salt thereof. The pharmaceutically acceptable salt is hydrochloride. The arthritis includes osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, reactive arthritis, systemic lupus erythematosus, polymyositis, or polymyalgia rheumatic.
Abstract:
PURPOSE: A monoclonal antibody which specifically detects proteins with a citrulline residue and a hybridoma cell line are provided to detect citrullinated proteins and to diagnose and treat autoimmune diseases. CONSTITUTION: A monoclonal antibody or an antigen-binding fragment thereof for diagnosing rheumatic arthritis contains a heavy chain variable region with an amino acid sequence of sequence number 3 and a light chain variable region with an amino acid of sequence number 4. The monoclonal antibody or the fragment is produced from a hybridoma(deposit number KCLRF-BP-00276). A method for providing information for diagnosing rheumatoid arthritis comprises a step of measuring antigen-antibody response of citrullinated proteins in a sample. A composition for diagnosing rheumatoid arthritis contains the monoclonal antibody or the fragment. A kit for diagnosing rheumatoid arthritis contains the antibody or the fragment. [Reference numerals] (AA) Cultivating Myeloma cell strain; (BB) Myeloma cell; (CC) Antigen; (DD) Spleen cell; (EE) Fusing in poly(ethylene glycol); (FF) Selecting and cultivating hybrid cells; (GG) Selecting antibody producing cells; (HH) Mass cultivating; (II) Producing clone; (JJ) Freezing; (KK) Thawing; (LL) Inducing tumor; (MM,NN) Antibody